Syndax Pharmaceuticals (SNDX) Operating Leases (2019 - 2025)

Syndax Pharmaceuticals' Operating Leases history runs 7 years deep, the most recent figure standing at $1.5 million for Q4 2025.

• In Q4 2025, Operating Leases fell 4.94% year-over-year to $1.5 million; the TTM figure through Dec 2025 stood at $1.5 million (down 4.94% YoY), while the FY2025 annual figure was $1.5 million, down 4.94% from the prior year.
• Operating Leases was $1.5 million for Q4 2025 at Syndax Pharmaceuticals, down from $1.6 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $1.6 million in Q4 2024 to a low of $22000.0 in Q2 2021.
• Historically, Operating Leases has averaged $684437.5 across 5 years, with a median of $676000.0 in 2022.
• The sharpest annual moves came in 2021 and 2022: Operating Leases slumped 90.83% in 2021, then jumped 2490.91% in 2022.
• A 5-year view of Operating Leases shows it stood at $711000.0 in 2021, then slipped by 0.28% to $709000.0 in 2022, then slipped by 18.48% to $578000.0 in 2023, then surged by 173.01% to $1.6 million in 2024, then retreated by 4.94% to $1.5 million in 2025.
• The last three Operating Leases figures came in at $1.5 million (Q4 2025), $1.6 million (Q4 2024), and $133000.0 (Q2 2024), per Business Quant data.